2024 Neuro-oncology Reading List

Reading List

Please click below to access the 2024 Neuro-oncology reading list.

C-cert Activity Description

The Continuous Certification (C-cert) activities provide subspecialty learning and knowledge assessment to ensure that diplomates are staying up to date on the latest science, treatments, and therapeutics relating to their subspecialty. The annual activities include: 1) reading the subspecialty  journal articles, and 2) taking and passing the 25-question online post-reading quiz to assess knowledge gained from the journal article content. 

Learning Objectives

• Integrate supportive care into neuro-oncologic care management
• Apply the results gathered from large patient populations in the management of primary brain tumor patients
• Discuss the management of neurologic and treatment complications in CNS tumors
• Give examples of new classifications and use of biomarkers in neuro-oncology

Core Competencies

• Medical Knowledge
• Patient Care
• Practice-Based Learning and Improvement

Continuing Medical Education (CME) Instructions

To claim CME credits, answer question 26 on the quiz to reflect the total time spent completing the required reading and online quiz. This question is not included in the scoring of the quiz. A passing score of 80% of higher is needed to meet C-cert requirements and receive CME credit. CME credit confirmation will be emailed within 24 hours of passing the quiz.

ACCME Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Academy of Neurology Institute (AANI) and United Council for Neurologic Subspecialties. The AANI is accredited by the ACCME to provide continuing medical education for physicians.

AMA Credit Designation Statement

The American Academy of Neurology Institute designates this enduring material for a maximum of 15 AMA PRA Category 1^TM credit(s). Physicians should claim only their credit commensurate with the extent of the participation in the activity.

ABPN Self-Assessment Designation Statement

The American Board of Psychiatry and Neurology (ABPN) has reviewed the UCNS Continuous Certification (C-cert) self-assessment activity and has approved this activity as part of a comprehensive self-assessment (SA) CME activity, which is mandated by the American Board of Medical Specialties (ABMS) as a necessary component of continuing certification.

Disclosures

The UCNS complies with all standards and policies of the ACCME, including identification and resolution of all conflicts of interest prior to the educational activity being delivered to learners. Accordingly, UCNS  planners, authors, and staff comply with the UCNS’s Conflicts of Interest Policy. 

2024 C-cert Activity Planner (Certification Council) Disclosures
All relevant financial relationships have been mitigated.

Neuro-oncology Certification Examination Committee Contributors

Christian Grommes, MD, Chair, Memorial Sloan Kettering Cancer Center
Disclosures: Received consultant fees from ONO, Roche, BTG, and Curis.

Andrea Wasilewski, MD, Vice Chair, Givens Brain Tumor Center
Disclosures: Received personal compensation from Novocure- device manufacturer, consultant; received personal compensation from Novocure- device manufacturer, ad hoc scientific advisor.

David M. Cachia, MD, UMass Memorial Medical Center
Disclosures: Received personal compensation for serving as a consultant to RedHill BioPharma Ltd, Guidepoint Global LLC, Dedham Group, and Gerson Lehrman Group; received personal compensation for being speaker for the Massachusetts Neurological Society. 

Cynthia J. Campen, MD, Stanford Medicine Children’s Health
Disclosures: Received compensation in 2022 for serving on the scientific advisory board for Alexion Pharmaceuticals regarding the patient experience for patients with NF1-associated plexiform neurofibromas who were receiving treatment with selumetinib; received compensation in 2022 for serving on a speaker's bureau for Medscape that was funded by Alexion Pharmaceuticals; received compensation for serving as an expert witness on approximately two cases annually for the last two years. For the cases in this timeframe, Dr. Campen served as an expert witness for the defense in medical malpractice cases; receives research support from the Greathouse Family Foundation for research investigating the neuroimaging biomarkers of NF1-associated cognitive dysfunction and gliomagenesis. The support funds 5% of her work effort as well as 50% salary of a data scientist who works for her. Also received funding from the Stanford Maternal and Child Research Institute for a research project investigating Neuroimaging of NF1-associated Optic Pathway Glioma. The funding paid 30% salary support for the data scientist.

Ashley P. Ghiaseddin, MD, University of Florida
Disclosures: Received personal compensation for having a consulting agreement with Neosoma; received personal compensation for serving on Advisory Board for Alexion Pharmaceuticals and on Advisory Board for Servier; held personal stock in Viatris Inc. 2022-2023 (have since sold). Have a consulting agreement with Monteris Medical and serve on advisory board for Aptitude Health.

Douglas E. Ney, MD, University of Colorado – Anschutz Medical Campus
Disclosures: Receive research support from Orbus Therapeutics and Denovo Biopharma.

Jerome J. Graber, MD, MPH, Alvord Brain Tumor Center
Disclosures: Received compensation for serving as an expert witness (reviewer) for Dickey Law Offices; participated with American Academy of Neurology, for consultant work on their educational products: Continuum, NeuroSAE and Question of the Day "app" and served on UCNS Neuroimaging Milestones Task Force and Neuroimaging certification exam committee.

Gurcharanjeet Kaur, MD, Columbia University Irving Medical Center
Disclosures: Received personal compensation for serving as a consultant for Alexion AstraZeneca rare disease; received personal compensation for serving on a speaker’s bureau for Alexion AstraZeneca rare disease.

Maria J. MacDonald, MD, London Health Sciences Ctr, Univ. of Western Ontario
Disclosures: Nothing to disclose.

Lauren Schaff, MD, Memorial Sloan Kettering Cancer Center
Disclosures: Received personal compensation for serving as a consultant for Ono Pharmaceutical Co, Resonance Health, and Guidepoint; received personal compensation for serving on a scientific advisory or data safety monitoring board for BTG, plc scientific advisory board; husband received personal compensation for serving as expert witness for Michie Hamlett Attorney at Law; received research support in the form of drug supply for IIT BTG, plc, research support AstraZeneca (site PI of clinical trial), DebioPharm (site PI of clinical trial); have intellectual property patent pending for use of low-dose glucarpidase for MTX clearance.

Roy E. Strowd, III, MD, Wake Forest Baptist Health
Disclosures: Received personal compensation in the form of royalties, Elsevier. Paid Instructor, Lecturio; received personal compensation for consulting, Novocure and Monteris Medical; receive personal compensation for serving as Editor, Neurology; received research support from National Institutes of Health; royalties, Elsevier.

Joon Uhm, MD, Mayo Clinic – Rochester 
Disclosures: Received personal compensation 2021 - CME honoraria for lectures on brain tumor therapies.

Staff Contact

Bryan Hagerla, Continuous Certification Manager
Disclosures: Nothing to disclose.
[email protected]
(612) 928-6326